Tweet
Sci Adv
. 2021 Jun 25;7(26):eabg4901.
doi: 10.1126/sciadv.abg4901. Print 2021 Jun.
Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test
Jacob T Heggestad 1 , David S Kinnamon 1 , Lyra B Olson 2 , Jason Liu 1 , Garrett Kelly 1 , Simone A Wall 1 , Solomon Oshabaheebwa 1 , Zachary Quinn 1 , Cassio M Fontes 1 , Daniel Y Joh 1 3 , Angus M Hucknall 1 , Carl Pieper 4 , Jack G Anderson 5 , Ibtehaj A Naqvi 6 , Lingye Chen 7 , Loretta G Que 7 , Thomas Oguin 3rd 8 , Smita K Nair 6 9 , Bruce A Sullenger 1 6 10 , Christopher W Woods 5 8 , Thomas W Burke 5 , Gregory D Sempowski 8 , Bryan D Kraft 7 , Ashutosh Chilkoti 11
Affiliations
- PMID: 34172447
- DOI: 10.1126/sciadv.abg4901
Abstract
Highly sensitive, specific, and point-of-care (POC) serological assays are an essential tool to manage coronavirus disease 2019 (COVID-19). Here, we report on a microfluidic POC test that can profile the antibody response against multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens-spike S1 (S1), nucleocapsid (N), and the receptor binding domain (RBD)-simultaneously from 60 μl of blood, plasma, or serum. We assessed the levels of antibodies in plasma samples from 31 individuals (with longitudinal sampling) with severe COVID-19, 41 healthy individuals, and 18 individuals with seasonal coronavirus infections. This POC assay achieved high sensitivity and specificity, tracked seroconversion, and showed good concordance with a live virus microneutralization assay. We can also detect a prognostic biomarker of severity, IP-10 (interferon-γ-induced protein 10), on the same chip. Because our test requires minimal user intervention and is read by a handheld detector, it can be globally deployed to combat COVID-19.